MedPage Today -- Type 2 diabetes patients taking an investigational drug targeting the PPAR-? receptor showed good glycemic control with few signs of the side effects associated with glitazone drugs.
MedPage Today -- Type 2 diabetes patients taking an investigational drug targeting the PPAR-? receptor showed good glycemic control with few signs of the side effects associated with glitazone drugs.